Archives: Agenda

• How firms redesigned delivery to increase margin, reduce risk and improve client outcomes.
• Real examples of firms /How they reduced rework, chasing, manual entry, onboarding delays
• How they used automation to remove friction, not replace people
• The measurable impact on margin, WIP, write downs, and client satisfaction/ What “good” looks like

Chairperson: Adil Bundeally, Transformation Director, Risk Advisor & Interim Executive, Lloyds (Former)

Chairperson: Ian Woodhouse, Strategy Advisor, Multrees Investor Services

• The Community Navigator (CN)- Patient Led Navigation demonstrating the feasibility
• Quantifiable Patient Improvement – increased Clinical Trials Knowledge and Beliefs Scale (CHEKS) scores
• Reframing Patient-Led Navigation – as a structured solution (option) vs traditional navigation model, to improve equity, patient experience, and engagement in oncology research

• Evolution of masking technology to achieve protease-mediated, tumor-specific drug activation
• Applications of masking technology in oncology and immunology, including the ubiquitous macrophage checkpoint, CD47, and cytokines
• Development of a China-inclusive early development path, including considerations of IITs, China IND, and US IND.

• Exploring the capability of Digital Display Labels (DDLs) and the benefits for Clinical Trial Supplies
• A demonstration of the functionality of DDLs; just in time labelling, lot and expiry update, multiple page count.
• Understanding the operational ability to securely & remotely update content and language.
• Integrating across IMP profiles, vials, bottles, blisters etc.